Company intelligence
Diasorin
About Diasorin
Headquartered in Italy and listed on the Italian Stock Exchange within the FTSE MIB Index, Diasorin is a global leader in the In Vitro Diagnostic (IVD) field and, since 2021, has been active in the Life Science business. For over 50 years, the Company has been developing, producing, and marketing reagent kits used by diagnostic laboratories worldwide. The Group operates across five continents through 35 companies, 4 branches, 10 manufacturing facilities, and 9 research and development centers. Our extensive diagnostic testing and life science offering, continuously enhanced through significant investments in research, positions Diasorin as the player with the broadest range of specialty tests available in the diagnostic market, identifying the Group as “The Diagnostic Specialist.” With a team of over 3,200 employees worldwide, including more than 400 researchers, we are committed to improving healthcare and enhancing people's quality of life. We value diversity, skills, and talent as key drivers of innovation and excellence, fostering an inclusive work environment that evolves alongside the ever-changing landscape of global healthcare.
Verified activity
Signals from Diasorin
4 published signals
Presence & Recognition
Diasorin is hosting an upcoming webinar titled Making a Case for Host-Response Diagnostics on September 21, 2026, featuring speakers Amin A. Mohammad, David M. Engman, and Brian DuChateau.
Reported by Diasorin
Presence & Recognition
Diasorin participated in a Labroots-hosted webinar hosted by Preeti Pancholi, PhD, D(ABMM), Co-Director of Clinical Microbiology and Director of Molecular Microbiology at The Ohio State University Wexner Medical Center, exploring the evolving role of clinical microbiology in addressing Candida auris.
Reported by Diasorin
Presence & Recognition
Diasorin is hosting an educational webinar on the clinical integration of rapid positive blood culture diagnostics for pediatric bloodstream infections at the upcoming Sepsis Alliance Summit 2026.
Reported by Diasorin
Research & Knowledge
Diasorin reported that plasma p-tau217 moved primary care physicians from roughly 65% to 93% accuracy in suspected Alzheimer’s off a routine blood draw.
Reported by Gabriele Allegri